Pfizer (PFE) Says FDA and EMA Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration accepted for filing and granted Priority Review ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE